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Strategies to investigate the possible existence of spo-
radic bovine spongiform encephalopathy (BSE) require
systematic testing programs to identify cases in countries
considered to have little or no risk for orally acquired dis-
ease or to detect a stable occurrence of atypical cases in
countries in which orally acquired disease is disappearing.
To achieve 95% statistical confidence that the prevalence
of sporadic BSE is no greater than 1 per million (i.e., the
annual incidence of sporadic Creutzfeldt-Jakob disease
[CJD] in humans) would require negative tests in 3 million
randomly selected older cattle. A link between BSE and
sporadic CJD has been suggested on the basis of labora-
tory studies but is unsupported by epidemiologic observa-
tion. Such a link might yet be established by the discovery
of a specific molecular marker or of particular combinations
of trends over time of typical and atypical BSE and various
subtypes of sporadic CJD, as their numbers are influenced
by a continuation of current public health measures that
exclude high-risk bovine tissues from the animal and
human food chains.
B
ovine spongiform encephalopathy (BSE) was first rec-
ognized in 1986 in the United Kingdom and quickly
reached epidemic proportions, affecting >30,000 cattle per
year by 1992. Because of continuing exportation of both
live cattle and meat and bone meal rendered from the car-
casses of slaughtered cattle, the disease spread throughout
most of Europe and a few non-European countries. By
2006, 20 years after its first appearance in the United
Kingdom, the disease had been reported in an additional
24 countries (1).
Beginning toward the end of the 1980s in the United
Kingdom, and in the 1990s in other countries, numerous
regulations were enacted to minimize the entry of contam-
inated tissues into both the animal and human food chains
and to eliminate the international spread of disease. These
measures have been extraordinarily successful, to the
extent that no new countries have been added to the list
during the past year and the number of new cases has dra-
matically diminished in most countries in which BSE has
appeared (the situation in some countries with insufficient
surveillance remains unclear).
Although the origin of the epidemic is thought to have
been caused by a species-crossing contamination by sheep
scrapie during the course of rendering and recycling car-
cass meat and bone meal as cattle feed, an alternative
hypothesis suggested an origin in a similarly recycled case
of spontaneously occurring disease in cattle. The pros and
cons of these competing ideas have been argued elsewhere
(2,3), and neither will ever be convincingly proved or dis-
proved. Thus, the phenomenon of spontaneous disease
remained in limbo until the recent discovery of “atypical”
strains of BSE reopened the question. In this article we
consider the importance of atypical BSE within the overall
concept of sporadic (spontaneous) disease and whether
such cases, if they exist, could account for at least some
cases of apparently sporadic Creutzfeldt-Jakob (CJD) in
humans.
Sporadic BSE
Obviously, the ideal country in which to examine the
question of sporadic BSE would have a large national herd
that was guaranteed never to have been exposed to envi-
ronmental sources of infection. Such an ideal will never be
realized. Until recently, the United States appeared to have
at least approached the ideal by having a large national
On the Question of Sporadic 
or Atypical Bovine Spongiform
Encephalopathy and 
Creutzfeldt-Jakob Disease 
Paul Brown,* Lisa M. McShane,† Gianluigi Zanusso,‡ and Linda Detwiler§
PERSPECTIVE
1816 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 12, No. 12, December 2006
*Bethesda, Maryland, USA; †National Institutes of Health,
Bethesda, Maryland, USA; ‡University of Verona, Verona, Italy;
and §Virginia-Maryland Regional College of Veterinary Medicine,
College Park, Maryland, USAherd, an adequate testing program, and an apparently small
risk for contamination by imported cattle or cattle feed.
That position was made vulnerable in late 2003 by the dis-
covery of a case of BSE imported from Canada and was
eliminated altogether by the subsequent discovery of 2
indigenously infected animals in widely separate regions
of the country. Although the 2 indigenous cases might rep-
resent sporadic disease, the continuing identification of
cases in western Canada, coupled with a history of sub-
stantial numbers of cattle imported from Canada into the
United States (both indigenous US animals had the same
molecular “signature” as the most recent Canadian case),
makes it difficult to ignore the possibility of undetected
instances of feed contamination from imported cattle and
recycled infectious carcasses.
At present, the 2 best countries in which to undertake
testing programs would be Argentina and Australia; both
have large national herds (≈50 million and 30 million ani-
mals, respectively), and both are considered to be free of
orally acquired BSE infections, on the basis of importation
history, nutritional practices, and adequacy of surveillance
(4). Even in these countries, however, the discovery of a
case of BSE could not be guaranteed to be spontaneous
because of the widespread global distribution of potential-
ly infected cattle and cattle feed and the vagaries of inter-
national trade: imperfect record keeping, lack of
compliance, and just plain deception.
By way of illustration, an incident occurred many years
ago that involved a particularly bulky shipment labeled as
a pesticide. The large quantity seemed unusual to the cus-
toms inspector, who opened it and discovered that the ship-
ment contained meat and bone meal destined to be spread
on fields to inhibit grazing by deer, a serious agricultural
pest. Thus, a study of sporadic BSE would only be truly
convincing if no cases were identified.
Moreover, the criteria for answering the question of
sporadic BSE are different than for orally acquired BSE.
Most importantly, we do not know at what age sporadic
cases of BSE might occur, but they are unlikely to be in the
3- to 5-year-old age group in which orally acquired BSE is
most prevalent. If the age distribution of sporadic disease
in cattle were to mimic that of sporadic CJD in humans, it
would not peak until 14–20 years of age (the last third of
the ≈20-year natural life span of a cow). Substantial num-
bers of such older cattle do not exist, and thus it may never
be possible to state with assurance that spontaneous BSE
does not occur.
Even if we accept this practical constraint, we can still
take advantage of the fact that in many countries a propor-
tion of the total slaughter population consists of breeding
stock and dairy cows that are culled at >7 years of age, and
animals that go directly to rendering plants or die “on
farm” further increase this number. Argentina, for exam-
ple, with a national herd of ≈50 million cattle, in 2005
recorded nearly 1.4 million deaths from slaughter and nat-
ural causes in animals >7 years (L. Mascitelli, pers.
comm.).  
Approximately 10% of cases of sporadic CJD occur in
patients 25–50 years of age (Figure 1); this age in humans
corresponds to the middle third of a cow’s normal life
span, or 7–13 years of age. If the age distribution of spo-
radic BSE followed the same pattern, negative test results
in a total of ≈3 million animals randomly selected from
this group would allow us to be 95% confident that spo-
radic BSE is not present at a prevalence >1 per million,
and ≈4.5 million negative animals would raise the level of
confidence to 99%. Larger numbers of BSE-negative ani-
mals would be required to achieve these levels of confi-
dence for a maximum prevalence <1 per 10 million cattle
(Table 1, Figure 2).
Even the least rigorous negative result—a prevalence
not greater than that of sporadic CJD in humans, or 1 per
million—would require several years to achieve, and it is
perhaps unrealistic to suppose that the motivation to pro-
long the testing program will endure much beyond the
global disappearance of orally acquired BSE and variant
CJD. Nevertheless, to the degree that testing older as well
as younger adult animals approached these numbers, both
statistical and consumer confidence would increase, and at
the very least provide reassurance that the occurrence of
sporadic disease must be exceedingly rare, with little like-
lihood of posing a risk to either human or animal nutrition.
Atypical BSE
Because of its contemporary nature, the study of atypi-
cal BSE is very much a work in progress, with compara-
tively little published data and many unknowns. The first 2
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Figure 1. Distribution of ages at onset of illness in 500 cases of
neuropathologically verified or experimentally transmitted sporadic
Creutzfeldt-Jakob disease. Approximately 10% of cases occur in
patients during the middle third (25–49 years) of a human lifespan,
which corresponds to age in cattle of ≈7–13 years.cases to be identified were a serendipitous discovery made
in the course of an unrelated experimental study that
required a detailed neuropathologic and immunochemical
examination of the entire brain (5). The absence of clinical
signs in these older animals, the unusual distribution of
PrPTSE, together with amyloid plaques, and a Western blot
pattern that differed from the stereotypic pattern seen in
typical BSE left little doubt about the probability that a
new “atypical strain” had been identified (bovine amy-
loidotic spongiform encephalopathy[BASE]).
Although no further cases were found in over 100
cattle examined in Italy, the initiation of Western blot stud-
ies of animals in other countries with screening test pro-
grams began to yield additional atypical patterns (Table 2,
Figure 3) (6–14; P. Lind, pers. comm.). Two major patterns
have been described, named L (resembling the original
Italian case pattern with a lower molecular weight than
typical BSE) and H (for a distinct pattern first seen in
France with a higher molecular weight than typical BSE).
It is not yet clear whether other mixed patterns result from
technical procedures in different laboratories or whether a
more complicated scheme of classification will evolve as
more atypical patterns are discovered.
In addition, Western blots of PrPTSE are a fragile basis
on which to define a BSE phenotype. Little or no informa-
tion is available about either the clinical status or neu-
ropathologic features of these animals. We know that cases
have occurred in different breeds and PrP genotypes, and
we also know that very few of the animals have had the
typical clinical picture of BSE (behavioral disturbances,
sensory signs, ataxia, and tremors), but a cloud of ambigu-
ity surrounds the clinical picture even in those animals for
which an extensive post-hoc investigation was undertaken.
The fact that few detailed neuropathologic results are
available is explained by the need to preserve at least a full
half brain for examination, which is presently not done in
any of the various countries that have screening test pro-
grams. In the future, the brain as well as the carcass must
be retained in cold storage until the test results are known.
The frequency of atypical cases is another unknown.
Published (7,12) and unpublished (11,13) observations indi-
cate that in some countries it might be as high as 5%–10%
of the total number of older animals diagnosed by rapid
screening tests (e.g., 2/27 in Germany, and 1/9 in Canada),
which would seem to be a surprisingly high proportion of
spontaneously occurring cases. However, data are not yet
sufficient to estimate the overall prevalence of atypical
BSE, i.e., cases per million tested animals of all ages.
In this context, a word is in order about the US testing
program. After the discovery of the first (imported) cow in
2003, the magnitude of testing was much increased, reach-
ing a level of >400,000 tests in 2005 (Figure 4). Neither of
the 2 more recently indigenously infected older animals
with nonspecific clinical features would have been detect-
ed without such testing, and neither would have been iden-
tified as atypical without confirmatory Western blots.
Despite these facts, surveillance has now been decimated
to 40,000 annual tests (USDA news release no. 0255.06,
July 20, 2006) and invites the accusation that the United
States will never know the true status of its involvement
with BSE.
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Figure 2. Maximum prevalence according to number of negative
cattle at 95% (solid line) and 99% (dashed line) confidence levels.
See Table 1 for exact numbers and statistical method.In short, a great deal of further work will need to be
done before the phenotypic features and prevalence of
atypical BSE are understood. More than a single strain
may have been present from the beginning of the epidem-
ic, but this possibility has been overlooked by virtue of the
absence of widespread Western blot confirmatory testing
of positive screening test results; or these new phenotypes
may be found, at least in part, to result from infections at
an older age by a typical BSE agent, rather than neonatal
infections with new “strains” of BSE. Neither alternative
has yet been investigated.
Sporadic CJD
The possibility that at least some cases of apparently
sporadic CJD might be due to infection by sporadic cases
of BSE cannot be dismissed outright. Screening programs
needed to identify sporadic BSE have yet to be implement-
ed, and we know from already extant testing programs that
at least a proportion of infected animals have no symptoms
and thus would never be identified in the absence of sys-
tematic testing. Thus, sporadic BSE (or for that matter,
sporadic disease in any mammalian species) might be
occurring on a regular basis at perhaps the same annual
frequency as sporadic CJD in humans, that is, in the range
of 1 case per million animals.
Whether humans might be more susceptible to atypical
forms of BSE cannot be answered at this time.
Experimentally transmitted BASE shows shorter incuba-
tion periods than BSE in at least 1 breed of cattle,
bovinized transgenic mice, and Cynomolgus monkeys
(12,13). In humanized transgenic mice, BASE transmitted,
whereas typical BSE did not transmit (13). Paradoxically,
the other major phenotype (H) showed an unusually long
incubation period in bovinized transgenic mice (12).
The limited experimental evidence bearing on a possi-
ble relationship between BSE and sporadic CJD is difficult
to interpret. The original atypical BASE strain of BSE had
a molecular protein signature very similar to that of 1 sub-
type (type 2 M/V) of sporadic CJD in humans (5). In
another study, a strain of typical BSE injected into human-
ized mice encoding valine at codon 129 showed a glyco-
pattern indistinguishable from the same subtype of
sporadic CJD (15). In a third study, the glycopatterns of
Bovine Spongiform Encephalopathy and CJD
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Figure 3. Representation of Western blots of PrPTSE patterns of
typical bovine spongiform encephalopathy (BSE) and the 2 major
types of atypical BSE. M.W., molecular weight in kilodaltons; L
type, atypical “light” pattern; H type, atypical “heavy” pattern. both the H and L strains of atypical BSE evidently did not
resemble any of the known sporadic CJD subtypes (12).
To these molecular biology observations can be added
the epidemiologic data accumulated during the past 30
years. The hypothesis that at least some cases of apparent-
ly sporadic CJD are due to unrecognized BSE infections
cannot be formally refuted, but if correct, we might expect
by now to have some epidemiologic evidence linking BSE
to at least 1 cluster of apparently sporadic cases of CJD.
Although only a few clusters have been found (and still
fewer published), every proposed cluster that has been
investigated has failed to show any common exposure to
bovines. For that matter, no common exposure has been
shown to any environmental vehicles of infection, includ-
ing the consumption of foodstuffs from bovine, ovine, and
porcine sources, the 3 livestock species known to be sus-
ceptible to transmissible spongiform encephalopathies.
Additional negative evidence comes from several large
case-control studies in which no statistically significant
dietary differences were observed between patients with
sporadic CJD and controls (16,17).
On the other hand, the difficulty of establishing a link
between BSE and CJD may be compounded by our igno-
rance of the infectious parameters of a sporadic form of
BSE (e.g., host range, tissue distribution of infectivity,
route of transmission, minimum infectious dose for
humans, whether single or multiple). Presumably, these
parameters would resemble those of variant CJD; that is,
high infectivity central nervous system and lymphoreticu-
lar tissues of an infected cow find their way into products
consumed by humans. Transmissions that might have
occurred in the past would be difficult to detect because
meat products are generally not distributed in a way that
results in detectable geographic clusters. 
Barring the discovery of a specific molecular signature
(as in variant CJD), the most convincing clue to an associ-
ation will come from the observation of trends over time of
the incidence of typical and atypical BSE and of sporadic
and variant CJD. With 4 diseases, each of which could
have increasing, unchanging, or decreasing trends, there
could be 81 (34) possible different combinations. However,
it is highly likely that the trends for typical BSE and vari-
ant CJD will both decrease in parallel as feed bans contin-
ue to interrupt recycled contamination. The remaining
combinations are thus reduced to 9 (32), and some of them
could be highly informative.
For example, if the incidence of atypical BSE declines
in parallel with that of typical BSE, its candidacy as a spo-
radic form of disease would be eliminated (because spo-
radic disease would not be influenced by current measures
to prevent oral infection). If, on the other hand, atypical
BSE continues to occur as typical BSE disappears, this
would be a strong indication that it is indeed sporadic, and
if in addition at least 1 form of what is presently consid-
ered as sporadic CJD (such as the type 2 M/V subtype
shown to have a Western blot signature like BASE) were
to increase, this would suggest (although not prove) a
causal relationship (Figure 5).
Recognition of the different forms of BSE and CJD
depends upon continuing systematic testing for both
bovines and humans, but bovine testing will be vulnerable
to heavy pressure from industry to dismantle the program
as the commercial impact of declining BSE cases ceases to
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Figure 4. Numbers of tested cattle in the United States,
2000–2007. Number tested in 2006 as of August 20; number test-
ed in 2007 proposed by the US Department of Agriculture.
Figure 5. Diagram of 2 possible informative trends in the incidence
of bovine spongiform encephalopathy (BSE) and Creutzfeld-Jakob
disease (CJD). The left panel shows the likely trends of typical
BSE and variant CJD (vCJD). The right upper panel shows 1 pos-
sible pair of trends of atypical BSE and sporadic CJD (sCJD) that
might occur in conjunction with the typical BSE/vCJD trends, and
would be consistent with the interpretation that atypical BSE is not
sporadic and is not related to sCJD. The right lower panel shows
a second possible associated pair of trends consistent with the
interpretation that atypical BSE is sporadic and might also be relat-
ed to the type 2 M/V subset of apparently sCJD. be an issue. Industry should be aware, however, of the
implications of sporadic BSE. Its occurrence would neces-
sitate the indefinite retention of all of the public health
measures that exclude high-risk bovine tissues from the
animal and human food chains, whereas its nonoccurrence
would permit tissues that are now destroyed to be used as
before, once orally acquired BSE has disappeared. 
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